Introduction: Simvastatin is a substance which is commonly used as a medicine to reduce cholesterol level. Unfortunately, it shows numerous side effects. Simvastatin affects various internal organs, and among other detriments to health may cause persistent muscle weakness, osteolytic processes, headaches, and rashes. Until now knowledge of the influence of simvastatin on bone marrow cells has been rather scant and fragmentary.
Material and Methods: During this experiment the numbers of all types of cells in the leukocytic system of porcine bone marrow were evaluated after 28 and 56 days of oral administration of simvastatin at a dose of 40 mg/day/animal.
Results: Simvastatin caused an increase in the number of all types of cells in the leukocytic system, and the most visible fluctuations concerned promyelocytes.
Conclusion: Observations obtained during the present study indicated that the results of the action of simvastatin on porcine bone marrow differ from those observed in other mammal species, including human. This may be due to various metabolic pathways within the bone marrow in the particular species, but the exact mechanisms of these actions are unknown at the present time.
1. Al-Ani B.: Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Saudi Med J 2013, 34, 477–483.
2. Al-Rasheed N.M., Al-Rasheed N.M., Hasan I.H., Al-Ajmi H.N., Mohamad R.A., Mahmoud A.M.: Simvastatin ameliorates diabetic cardiomyopathy by attenuating oxidative stress and inflammation in rats. Oxid Med Cell Longev 2017, doi: 10.1155/2017/1092015.
3. Antons K.A., Williams C.D., Baker S.K., Phillips P.S.: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006, 119, 400–409.
4. Black A.E., Hayes R.N., Roth B.D., Woo P., Woolf T.F.: Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 2000, 27, 916–992.
5. Buhaescu I., Izzedine H.: Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007, 40, 575–584.
6. Chang C.C., Chiu P.F., Chen H.L., Chang T.L., Chang Y.J., Huang C.H.: Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells. Hemodial Int 2013, 17, 116–121.
7. Chello M., Anselmi A., Spadaccio C., Patti G., Goffredo C., Di Sciascio G., Covino E.: Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 2007, 83, 1374–1380.
8. Chello M., Patti G., Candura D., Mastrobuoni S., Di Sciascio G., Agro F., Carassiti M., Covino E.: Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006, 34, 660–667.
9. Edwards C.J., Hart D.J., Spector T.D.: Oral statin and increased bone mineral density in postmenopausal women. Lancet, 2000, 355, 2218–2219.
10. Endres M.: Statins: potential new indications in inflammatory conditions. Atheroscler Suppl 2006, 7, 31–35.
11. Fan J., Rone M.B., Papadopoulos V.: Translocator protein 2 is involved in cholesterol redistribution during erythropoiesis J Biol Chem 2009, 284, 30484–30497.
12. Fathi H.A., Allam A., Elsabahy M., Fetih G., El-Badry M.: Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf B Biointerfaces 2017, 28, 236–245.
13. Glińska K., Nicpoń J., Pawlas M.: Mechanism of action statins and possibilities of their application in dog therapy. Med Weter 2006, 62, 254–256.
14. Godfrey L.M., Erramouspe J., Cleveland K.W.: Teratogenic risk of statins in pregnancy. Ann Pharmacother 2012, 46, 1419–1424.
15. Huang X., Liang Y., Yang Y., Lu X.: Single-step production of the simvastatin precursor monacolin J by engineering of an industrial strain of Aspergillus terreus. Metab Eng 2017, 42, 109–114.
16. Ii M., Losordo D.W.: Statins and the endothelium. Vasc Pharmacol 2007, 46, 1–9.
17. Matsuzawa Y., Kita T., Mabuchi H., Matsuzako M., Nakaya N., Oikawa S., Saito Y., Sasaki J., Shimamoto K., Itakura H.: The J-LIT group: sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effect in 51,321 Japanese hypercholesterolemic patients implication of the J-LIT study, a large scale nationwide cohort study. Circ J 2003, 67, 287–294.
18. Mohammadian M., Sadeghipour H.R., Kashani I.R., Jahromi G.P., Omidi A., Nejad A.K., Golchoobian R., Boskabady M.H.: Evaluation of simvastatin and bone marrow-derived mesenchymal stem cell combination therapy on airway remodeling in a mouse asthma model. Lung 2016, 194, 777–785.
19. Namazi M.R., Handjani F., Sodaifi M.: The potential utility of statins as novel weapons against graft-versus-host disease. Med Hypotheses 2005, 65, 1203–1204.
20. Newman A., Clutterbuck R.D., Powles R.L., Millar J.L.: Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. Leukemia 1994, 8, 274–280.
21. Nomura T.: Japanese clinical statistical data of patients with aplastic anemia. Nippon Rinsho 1992, 50, 735–746.
22. Piorkowski M., Fisher S., Stellbaum C., Jaster M., Martus P., Morguet A.J., Schultheiss H.P., Rauch U.: Treatment with ezetimibe plus low-dose Atorvastatin compared with higher-dose Atorvastatin alone. J Am Coll Cardiol 2007, 48, 1035–1042.
23. Pucetti L., Bruni F., Bova G., Cercignani M., Pompella A., Auteri A., Pasqui A.I.: Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolaemia subjects. In vivo effect of cerivastatin. Int J Clin Lab Res 2000, 30, 147–156.
24. Shahbazian H., Atrian A., Yazdanpanah L., Lashkarara G.R., Zafar Mohtashami A.: Anti-inflammatory effect of simvastatin in hemodialysis patients. Jundishapur J Nat Pharm Prod 2015, 10, el17962.
25. Shimamura M., Urabe A., Takaku F., Mizuno M.: Effects of dolichol and dolichyl phosphate on in vitro differentiation of hematopoietic progenitors. Int J Cell Cloning 1985, 3, 313–319.
26. Slawinska A., Kandefer-Szerszen M.: The anticancer properties of statins. Postępy Hig Med Dosw 2008, 62, 393–404.
27. Snarska A., Gonkowski S., Rytel L., Pomianowski A., Babińska I., Otrocka-Domagała I., Żarczyńska K., Wysocka D., Sobiech P.: Influence of simvastatin on red blood cell line in porcine bone marrow. Pol J Vet Sci 2017, 4, 811–814.
28. Sukpat S., Isrrasena N., Patumraj S.: Pleiotropic effects of simvastatin on wound healing in diabetic mice. J Med Assoc Thai 2016, 99, 213–219.
29. Tun T., Kang Y.S.: Effects of simvastatin on CAT-1 mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lined (TR-iBRB). Microvasc Res 2017, 111, 60–66.
30. Vilimanovich U., Bosnjak M., Bogdanovic A., Markovic I., Isakovic A., Kravic-Stevovic T., Mircic A., Trajkovic V., Bumbasirevic V.: Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells. Eur J Pharmacol 2015, 15, 415–428.
31. Wong M.J., Kantores C., Ivanovska J., Jain A., Jankov R.P.: Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling. Am J Physiol Lung Cell Mol Physiol 2016, 311, 985–999.